Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
We performed integrative molecular analyses of over time samples from patients with ATL and asymptomatic HTLV-1 carriers (AC) to provide direct evidence of molecular time and disease progression and to identify the common epigenetic abnormalities. We found that the HTLV-1 infected cells from all infected individuals including patients with ATL and also AC with low proviral loads showed abnormal transcriptome with largely common pattern. ATAC-seq and ChIP-seq revealed that epigenetic dysregulation of infected cells is a background characteristic of the abnormal transcriptome. Importantly, disease-specific chromatin structure and histone modification pattern are involved in the progression of infected cells. The results provide the possible mechanism of virus-associated epigenetic abnormality that is a molecular basis of ATL development. Furthermore, we successfully identified some important functional genes involved in the pathogenesis of ATL.
|